Merck & Co., Inc. $MRK Shares Sold by Diversified Management Inc.

Diversified Management Inc. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 38.7% during the second quarter, Holdings Channel reports. The fund owned 8,961 shares of the company’s stock after selling 5,662 shares during the quarter. Diversified Management Inc.’s holdings in Merck & Co., Inc. were worth $1,151,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Generali Investments Management Co LLC increased its stake in shares of Merck & Co., Inc. by 36.0% in the second quarter. Generali Investments Management Co LLC now owns 58,747 shares of the company’s stock worth $7,549,000 after buying an additional 15,556 shares during the last quarter. E. Ohman J or Asset Management AB raised its holdings in Merck & Co., Inc. by 3.3% in the second quarter. E. Ohman J or Asset Management AB now owns 87,897 shares of the company’s stock valued at $11,295,000 after acquiring an additional 2,840 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in Merck & Co., Inc. by 5.1% during the 2nd quarter. Handelsbanken Fonder AB now owns 1,959,794 shares of the company’s stock valued at $251,834,000 after acquiring an additional 95,489 shares during the last quarter. City Holding Co. boosted its stake in Merck & Co., Inc. by 1.0% during the 2nd quarter. City Holding Co. now owns 11,085 shares of the company’s stock valued at $1,424,000 after acquiring an additional 109 shares during the last quarter. Finally, Charles Schwab Trust Co boosted its stake in Merck & Co., Inc. by 4.2% during the 2nd quarter. Charles Schwab Trust Co now owns 8,250 shares of the company’s stock valued at $1,060,000 after acquiring an additional 330 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $130.35 on Wednesday. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.05. The stock’s fifty day moving average is $124.58 and its 200-day moving average is $119.47. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market capitalization of $321.59 billion, a price-to-earnings ratio of 104.28, a price-to-earnings-growth ratio of 5.66 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Analyst Upgrades and Downgrades

MRK has been the subject of several research analyst reports. BMO Capital Markets boosted their target price on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Barclays boosted their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Argus raised their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. lifted their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Finally, Morgan Stanley boosted their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Fourteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $135.11.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA and European Medicines Agency accepted supplemental applications to expand ENFLONSIA, Merck’s RSV preventive therapy, to additional high-risk young children. The potential broader indication could expand Merck’s infectious-disease portfolio and help diversify revenue beyond oncology. Merck Wins FDA and EMA Review for Broader RSV Use in Children
• Positive Sentiment: Argus raised its price target on MRK from $130 to $145 and reiterated a “buy” rating, adding to a generally favorable analyst view. Recent targets from other firms have also reached the $146–$150 range, reflecting confidence in Keytruda, animal health and the development pipeline.
• Positive Sentiment: Merck’s latest quarterly results exceeded expectations, with revenue of $16.61 billion versus a $16.37 billion consensus estimate and revenue growth of 5.1% year over year. Oncology and animal health were key contributors, while the company maintained 2026 adjusted EPS guidance of $2.66–$2.76. Merck Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Merck declared a quarterly dividend of $0.85, equivalent to $3.40 annually and a yield of roughly 2.6%. The dividend supports the stock’s income appeal, although the reported payout ratio is elevated because current earnings are depressed by unusual factors.
• Neutral Sentiment: Reports discussing a proposal to separate the measles, mumps and rubella vaccine into three shots could create uncertainty around Merck’s vaccine business, including MMR II. Experts say the plan lacks scientific support and is unlikely to proceed. Trump Wants to Split the MMR Vaccine
• Negative Sentiment: Analysts continue to flag falling estimates and the risk from upcoming Keytruda patent expirations, which could pressure Merck’s near-term growth and valuation despite strong current sales and pipeline progress. MRK Stock Up 5.6% in a Month as Estimates Fall
• Negative Sentiment: Executive Vice President Richard Deluca sold 6,050 shares worth approximately $788,799. The sale reduced his holdings by 3.75%, though he continues to own a substantial position and the transaction alone is not necessarily a signal of deteriorating fundamentals. Merck EVP Sells Stock

Insider Activity at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the transaction, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 92,603 shares of company stock valued at $11,966,744. Insiders own 0.17% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.